Skip to main content

Advertisement

SpringerLink
Log in

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int J Hematol. 2016;103:86–94.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

Author information

Authors and Affiliations

  1. Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Kensei Tobinai

  2. Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

    Toshiki Uchida

  3. Tohoku University Hospital, Sendai, Japan

    Noriko Fukuhara

  4. Janssen Pharmaceutical K.K., Tokyo, Japan

    Tomoaki Nishikawa

Authors
  1. Kensei Tobinai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noriko Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoaki Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kensei Tobinai.

Ethics declarations

Conflict of interest

KT received grants and personal fees from Celgene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Mundipharma, Ono, Takeda; personal fees from HUYA and Zenyaku Kogyo; grants from AbbVie, GSK SERVIER. NF received grants from Janssen. TU received personal fees from BMS, Celgene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Novartis, Mundipharma, Nippon Shinyaku, Otsuka, Pfizer Takeda. TN is employed by Janssen.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Trial registration

NCT01704963 (ClinicalTrials.gov).

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tobinai, K., Uchida, T., Fukuhara, N. et al. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study. Int J Hematol 109, 366–368 (2019). https://doi.org/10.1007/s12185-018-02577-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-018-02577-8

Search

Navigation